Marc R Mansour

List of Publications by Year
in descending order

46 papers	4,324 citations	279798 23 h-index	289244 40 g-index
46 all docs	46 docs citations	46 times ranked	7421 citing authors

#	Article	IF	Citations
1	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation, 2008, 118, 3143-3150.	8.2	1,069
2	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	12.6	665
3	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	27.8	355
4	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009, 114, 5136-5145.	1.4	346
5	Notch signaling: switching an oncogene to a tumor suppressor. Blood, 2014, 123, 2451-2459.	1.4	225
6	Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood, 2009, 113, 4381-4390.	1.4	154
7	<scp>KPT</scp>â€330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)â€mediated nuclear export has selective antiâ€leukaemic activity in preclinical models of <scp>T</scp>â€cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 2013, 161, 117-127.	2.5	149
8	Therapeutic targeting of â€œundruggableâ€•MYC. EBioMedicine, 2022, 75, 103756.	6.1	136
9	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	10.3	124
10	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	1.4	111
11	Prognostic Implications of <i>NOTCH1</i> and <i>FBXW7</i> Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol. Journal of Clinical Oncology, 2009, 27, 4352-4356.	1.6	108
12	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2013, 210, 1545-1557.	8.5	107
13	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	8.5	104
14	Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications, 2017, 8, 14385.	12.8	76
15	Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2007, 13, 6964-6969.	7.0	70
16	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 3221-3226.	1.4	61
17	A Zebrafish Model of Myelodysplastic Syndrome Produced through <i>tet2</i> Genomic Editing. Molecular and Cellular Biology, 2015, 35, 789-804.	2.3	58
18	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	1.3	56

#	Article	IF	Citations
19	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood, 2014, 124, 106-110.	1.4	50
20	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2017, 7, 1336-1353.	9.4	48
21	*EZH2*-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress. Cancer Discovery, 2020, 10, 998-1017.	9.4	29
22	Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. ELife, 2016, 5, .	6.0	29
23	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood, 2022, 140, 25-37.	1.4	29
24	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood, 2020, 135, 1685-1695.	1.4	28
25	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	8.5	22
26	Targeting oncogenic interleukinâ€7 receptor signalling with *N*â€acetylcysteine in T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2015, 168, 230-238.	2.5	20
27	Disruption of *asxl1* results in myeloproliferative neoplasms in zebrafish. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	18
28	Successful remission induction therapy with gilteritinib in a patient with *de novo FLT3*â€mutated acute myeloid leukaemia and severe COVIDâ€19. British Journal of Haematology, 2020, 190, e189-e191.	2.5	17
29	Current and emerging therapeutic approaches for Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 194, 28-43.	2.5	16
30	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. Blood Advances, 2020, 4, 4665-4668.	5.2	11
31	The role of noncoding mutations in blood cancers. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	9
32	In *trans* early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation. British Journal of Haematology, 2020, 188, e53-e57.	2.5	6
33	Prognostic impact of the absence of biallelic deletion at the *TRG* locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial. Haematologica, 2018, 103, e288-e292.	3.5	5
34	Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma. Cancer Cell, 2011, 20, 559-561.	16.8	3
35	High Incidence of Notch-1 Mutations in Adult Patients with T-Cell Acute Lymphoblastic Leukaemia.. Blood, 2005, 106, 1447-1447.	1.4	3
36	Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma. Expert Review of Hematology, 2009, 2, 133-136.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Leukemia, 2021, , .	7.2	2
38	A role for aberrant Notch signaling in acute myeloid leukemia?. Leukemia and Lymphoma, 2006, 47, 2280-2281.	1.3	1
39	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. Oncogene, 2021, 40, 5718-5729.	5.9	1
40	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 194, i4-i4.	5.2	1
41	Chromosomal Translocations and Gene Rearrangements in Acute Lymphoblastic Leukaemia. , 2015, , 189-222.		0
42	The TAL1 Complex Represses the FBXW7 Tumor Suppressor Through Mir-223 in Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1296-1296.	1.4	0
43	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	1.4	0
44	Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	1.4	0
45	A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia. Blood, 2013, 122, 1273-1273.	1.4	0
46	ÂSelective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. Blood, 2014, 124, 995-995.	1.4	0